Fig. 4From: Recombinant human adenovirus-p53 therapy for the treatment of nasopharyngeal carcinoma: a meta-analysisForest plot for the meta-analysis of the 2 year disease-free survival (DFS) rate, recurrence-free survival (RFS) rate and distant metastases-free survival (DMFS) rateBack to article page